WCN26-7702 Effect of severe renal dysfunction on the pharmacokinetics of DNA-reactive platinum after oxaliplatin administration

Read full text Summarise with VIRAT
Authors: Shunsaku Nakagawa, Aimi Shimazaki, Taro Funakoshi, Atsushi Yonezawa, Shigeki Kataoka, Takahiro Horimatsu, Daiki Hira, Kotaro Itohara, Satoshi Imai, Takayuki Nakagawa, Takeshi Matsubara, Motoko Yanagita
+3 more Manabu Muto, Kazuo Matsubara, Tomohiro Terada
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Higher amounts of circulating ultrafilterable platinum (fPt) are found in patients with renal dysfunction receiving a constant dose of oxaliplatin. However, it has been suggested that the increased systemic exposure of fPt do not increase oxaliplatin-induced toxicities. We hypothesized that the kidney has minimal effect on the elimination rate of reactive fPt. In this study, we aimed to quantify DNA-reactive fPt in plasma and to evaluate the impact of severe renal dysfunction on its pharmacokinetics.

Fields of Study & Subjects

Metal complexes synthesis and properties Chemotherapy-induced organ toxicity mitigation Pharmacogenetics and Drug Metabolism

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104171–104171
Publication date
25 March 2026
Language
EN